

Depomed Inc (DEPO) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/DD38E039C34EN.html>

Date: June 2018

Pages: 51

Price: US\$ 125.00 (Single User License)

ID: DD38E039C34EN

Abstracts

Depomed Inc (DEPO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities – A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Depomed Inc (Depomed) is a specialty pharmaceutical company that develops and commercializes drugs indicated for the treatment of pain and other diseases of the central nervous system. Its product portfolio comprise products for treatment of indications including postherpetic neuralgia caused due to viral infection, herpes zoster, or nerve damage; management of mild to moderate acute pain in adults; migraine attacks in adults of 18 years of age or above; and pain in cancer patients of 18 years of age and older. The company sells its products to wholesale distributors and retail pharmacies. Depomed also licenses Acuform, its proprietary gastroretentive drug delivery technology. Depomed is headquartered in Newark, California, the US.

Depomed Inc Key Recent Developments

Jun 05,2018: Depomed Appoints Phillip B. Donenberg As Chief Financial Officer

May 10,2018: Depomed Announces First-Quarter 2018 Financial Results

Apr 17,2018: Depomed Named John B. Thomas as Senior Vice President, Investor Relations and Corporate Communications

Apr 17,2018: Depomed Announces Appointment Of John B. Thomas As Senior Vice President, Investor Relations And Corporate Communications

Apr 02,2018: Depomed Announces the Appointment of Stan Bukofzer as Senior Vice President and Chief Medical and Scientific Officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Depomed Inc - Key Facts
Depomed Inc - Key Employees
Depomed Inc - Key Employee Biographies
Depomed Inc - Major Products and Services
Depomed Inc - History
Depomed Inc - Company Statement
Depomed Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Depomed Inc - Business Description
Product Category: CAMBIA
Overview
Performance
Product Category: Gralise
Overview
Performance
Product Category: Lazanda
Overview
Performance
Product Category: NUCYNTA Products
Overview
Performance
Product Category: Zipsor
Overview
Performance
R&D Overview
Depomed Inc - Corporate Strategy
Depomed Inc - SWOT Analysis
SWOT Analysis - Overview
Depomed Inc - Strengths
Depomed Inc - Weaknesses

Depomed Inc - Opportunities
Depomed Inc - Threats
Depomed Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Depomed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Depomed Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Depomed Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

May 10, 2018: Depomed Announces First-Quarter 2018 Financial Results
Apr 17, 2018: Depomed Announces Appointment Of John B. Thomas As Senior Vice President, Investor Relations And Corporate Communications
Apr 02, 2018: Depomed Announces the Appointment of Stan Bukofzer as Senior Vice President and Chief Medical and Scientific Officer
Mar 19, 2018: Depomed Announces New Corporate Headquarters
Nov 07, 2017: Depomed Announces Third Quarter 2017 Financial Results
Oct 18, 2017: Depomed Announces Appointment of Santosh J. Vetticaden, M.D., PH.D. as Senior Vice President, Chief Medical and Scientific Officer
Aug 07, 2017: Depomed Announces Second Quarter 2017 Financial Results
May 09, 2017: Depomed Announces First Quarter 2017 Financial Results and Strategic Initiatives Aimed at Driving Sustainable Long-Term Growth and Shareholder Value
Apr 25, 2017: Depomed Announces Appointment of Sharon D. Larkin as Senior Vice President, Human Resources and Administration
Feb 21, 2017: Depomed Reports Fourth Quarter and Full Year 2016 Financial Results

SECTION 6 – APPENDIX

[Methodology](#)
[Ratio Definitions](#)
[About GlobalData](#)
[Contact Us](#)
[Disclaimer](#)

List Of Tables

LIST OF TABLES

Depomed Inc, Key Facts
Depomed Inc, Key Employees
Depomed Inc, Key Employee Biographies
Depomed Inc, Major Products and Services
Depomed Inc, History
Depomed Inc, Subsidiaries
Depomed Inc, Key Competitors
Depomed Inc, Ratios based on current share price
Depomed Inc, Annual Ratios
Depomed Inc, Annual Ratios (Cont.1)
Depomed Inc, Annual Ratios (Cont.2)
Depomed Inc, Interim Ratios
Depomed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Depomed Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Depomed Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Depomed Inc, Performance Chart (2013 - 2017)

Depomed Inc, Ratio Charts

Depomed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Depomed Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

COMPANIES MENTIONED

Purdue Pharma LP

Pernix Therapeutics Holdings Inc

Insys Therapeutics Inc

Arbor Pharmaceuticals LLC

I would like to order

Product name: Depomed Inc (DEPO) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/DD38E039C34EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DD38E039C34EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970